Study population and transplant characteristics
| Characteristic . | Value . |
|---|---|
| Sample size, no. | 80 |
| Patient age, median (range) | 56.9 (7.6-70.5) |
| Donor age, median (range) | 42.8 (19.3-66.4) |
| Patients aged >60 years | 31 (39%) |
| Patient sex (male) | 52 (65%) |
| Donor sex (male) | 43 (54%) |
| Female donor to male patients | 21 (26%) |
| CMV seronegative donor-recipient pair | 37 (46%) |
| Diagnosis | |
| Myeloid malignancies | 46 (57%) |
| Acute myeloid leukemia | 33 (41%) |
| Myelodysplastic syndrome | 8 (10%) |
| Myeloproliferative neoplasm | 4 (5%) |
| BPDCN | 1 (1%) |
| Lymphoid malignancies | 34 (43%) |
| Acute lymphoblastic leukemia | 8 (10%) |
| Non-Hodgkin lymphoma | 17 (21%) |
| Hodgkin disease | 3 (4%) |
| Chronic lymphocytic leukemia | 3 (4%) |
| Multiple myeloma | 3 (4%) |
| Disease risk index | |
| Low | 10 (13%) |
| Intermediate | 53 (66%) |
| High | 13 (16%) |
| Very high | 4 (5%) |
| Previous transplant | |
| ASCT | 15 (19%) |
| allo-SCT | 1 (1%) |
| Donor type | |
| HLA-matched relative | 28 (35%) |
| HLA-matched unrelated donor | 40 (50%) |
| HLA-mismatched unrelated donor | 12 (15%) |
| Conditioning regimen | |
| MAC | 15 (19%) |
| Flu-Bu | 12 (15%) |
| Bu-Cy | 1 (1%) |
| Cy-TBI | 2 (3%) |
| RIC | 65 (81%) |
| Flu-Bu | 48 (60%) |
| Flu-TBI | 1 (1%) |
| Clo-Bu | 12 (15%) |
| Clo-TBI | 1 (1%) |
| Flu–Mel | 3 (4%) |
| TBI based regimen | |
| Yes | 4 (5%) |
| No | 76 (95%) |
| ATG | |
| Yes | 73 (91%) |
| No | 7 (9%) |
| GVHD prophylaxis | |
| CsA + MMF | 47 (59%) |
| CsA + MTX | 6 (7%) |
| CsA | 27 (34%) |
| Median follow-up, months (range) | 36.6 (12.5-60.1) |
| Characteristic . | Value . |
|---|---|
| Sample size, no. | 80 |
| Patient age, median (range) | 56.9 (7.6-70.5) |
| Donor age, median (range) | 42.8 (19.3-66.4) |
| Patients aged >60 years | 31 (39%) |
| Patient sex (male) | 52 (65%) |
| Donor sex (male) | 43 (54%) |
| Female donor to male patients | 21 (26%) |
| CMV seronegative donor-recipient pair | 37 (46%) |
| Diagnosis | |
| Myeloid malignancies | 46 (57%) |
| Acute myeloid leukemia | 33 (41%) |
| Myelodysplastic syndrome | 8 (10%) |
| Myeloproliferative neoplasm | 4 (5%) |
| BPDCN | 1 (1%) |
| Lymphoid malignancies | 34 (43%) |
| Acute lymphoblastic leukemia | 8 (10%) |
| Non-Hodgkin lymphoma | 17 (21%) |
| Hodgkin disease | 3 (4%) |
| Chronic lymphocytic leukemia | 3 (4%) |
| Multiple myeloma | 3 (4%) |
| Disease risk index | |
| Low | 10 (13%) |
| Intermediate | 53 (66%) |
| High | 13 (16%) |
| Very high | 4 (5%) |
| Previous transplant | |
| ASCT | 15 (19%) |
| allo-SCT | 1 (1%) |
| Donor type | |
| HLA-matched relative | 28 (35%) |
| HLA-matched unrelated donor | 40 (50%) |
| HLA-mismatched unrelated donor | 12 (15%) |
| Conditioning regimen | |
| MAC | 15 (19%) |
| Flu-Bu | 12 (15%) |
| Bu-Cy | 1 (1%) |
| Cy-TBI | 2 (3%) |
| RIC | 65 (81%) |
| Flu-Bu | 48 (60%) |
| Flu-TBI | 1 (1%) |
| Clo-Bu | 12 (15%) |
| Clo-TBI | 1 (1%) |
| Flu–Mel | 3 (4%) |
| TBI based regimen | |
| Yes | 4 (5%) |
| No | 76 (95%) |
| ATG | |
| Yes | 73 (91%) |
| No | 7 (9%) |
| GVHD prophylaxis | |
| CsA + MMF | 47 (59%) |
| CsA + MTX | 6 (7%) |
| CsA | 27 (34%) |
| Median follow-up, months (range) | 36.6 (12.5-60.1) |
ASCT, autologous stem cell transplantation; BPDCN, blastic plasmacytoid dendritic cell neoplasm; Bu, busulfan; Clo, Clofarabine; Cy, cyclophosphamide; Flu, fludarabine; Mel, melphalan; MMF, mycophenolate mofetil; MTX, methotrexate; TBI, total body irradiation.